title: Up to date in pharmacological treatment of dilated cardiomyopathy.
abstract: Dilated cardiomyopathy is a syndrome characterized by dilatation and impaired function of one or both ventricles and represents the most common heart failure entity requiring heart transplantation. The treatment we currently use does not directly influence specific underlying pathomechanisms of this disorder, and several attempts are being made in order to introduce more specific therapies. We summarized the most important pharmacological strategies that are being evaluated for the treatment of dilated cardiomyopathy and pointed out the novel therapeutic approaches concerning heart failure secondary to this clinical condition.
authors.affiliation: Institute of Cardiovascular Disease Prof Dr C.C. Iliescu, Bucharest, Romania.
authors.forename: Carmen
authors.initials: C
authors.lastname: Ginghina
authors.forename: Andreea
authors.initials: A
authors.lastname: Teodorescu
authors.forename: Ioana
authors.initials: I
authors.lastname: Stoian
authors.forename: Marinela
authors.initials: M
authors.lastname: Serban
authors.forename: Ioana
authors.initials: I
authors.lastname: Ghiorghiu
authors.forename: Karola
authors.initials: K
authors.lastname: Wohlfart
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000998:Antiviral Agents; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone